NCT00477087View on ClinicalTrials.gov

Phase II GM-CSF Plus Mitoxantrone in Hormone Refractory Prostate Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

July 31, 2006

Primary Completion Date

October 31, 2009

Study Completion Date

January 31, 2010

Conditions
Prostatic Neoplasms
Interventions
DRUG

Mitoxantrone

Mitoxantrone is an anti-cancer chemotherapy drug that is classified as an antitumor antibiotic.

DRUG

GM-CSF

GM-CSF is a biologic response modifier, classified as a colony stimulating factor.

Trial Locations (1)

94305

Stanford University School of Medicine, Stanford

Sponsors

Collaborators (1)

Bayer
All Listed Sponsors
collaborator

Bayer

INDUSTRY

lead

Stanford University

OTHER